Post hoc analyses in sepsis trials: A formula for disappointment?

[1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941

[2] DIVERGENT EFFICACY OF ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA IN INTRAVASCULAR AND PERITONITIS MODELS OF SEPSIS [J]. JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (01) : 83 - 88

[3] A 2ND LARGE CONTROLLED CLINICAL-STUDY OF E5, A MONOCLONAL-ANTIBODY TO ENDOTOXIN - RESULTS OF A PROSPECTIVE, MULTICENTER, RANDOMIZED, CONTROLLED TRIAL [J]. CRITICAL CARE MEDICINE, 1995, 23 (06) : 994 - 1006

[4] SEPSIS CLINICAL-TRIALS - QUIXOTE,DON REVISITED [J]. CHEST, 1995, 107 (02) : 298 - 299

[5] COMPARTMENTALIZATION OF THE ACUTE CYTOKINE RESPONSE IN HUMANS AFTER INTRAVENOUS ENDOTOXIN ADMINISTRATION [J]. JOURNAL OF APPLIED PHYSIOLOGY, 1993, 74 (06) : 3027 - 3033

[6] HIGH CIRCULATING LEVELS OF INTERLEUKIN-6 IN PATIENTS WITH SEPTIC SHOCK - EVOLUTION DURING SEPSIS, PROGNOSTIC VALUE, AND INTERPLAY WITH OTHER CYTOKINES [J]. AMERICAN JOURNAL OF MEDICINE, 1991, 91 (01) : 23 - 29

[7] PLASMA CYTOKINE AND ENDOTOXIN LEVELS CORRELATE WITH SURVIVAL IN PATIENTS WITH THE SEPSIS SYNDROME [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (08) : 771 - 778

[8] STRATEGIES FOR BLOCKING THE SYSTEMIC EFFECTS OF CYTOKINES IN THE SEPSIS SYNDROME [J]. CRITICAL CARE MEDICINE, 1995, 23 (05) : 955 - 963

[9] TUMOR-NECROSIS-FACTOR AS THE PROXIMAL MEDIATOR OF SEPSIS - OR THIS TOO WILL PASS [J]. CRITICAL CARE MEDICINE, 1995, 23 (09) : 1457 - 1458

[10] DELLINGER RP, 1992, UPDATE INTENSIVE CAR, V16, P289

[1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941

[2] DIVERGENT EFFICACY OF ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA IN INTRAVASCULAR AND PERITONITIS MODELS OF SEPSIS [J]. JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (01) : 83 - 88

[3] A 2ND LARGE CONTROLLED CLINICAL-STUDY OF E5, A MONOCLONAL-ANTIBODY TO ENDOTOXIN - RESULTS OF A PROSPECTIVE, MULTICENTER, RANDOMIZED, CONTROLLED TRIAL [J]. CRITICAL CARE MEDICINE, 1995, 23 (06) : 994 - 1006

[4] SEPSIS CLINICAL-TRIALS - QUIXOTE,DON REVISITED [J]. CHEST, 1995, 107 (02) : 298 - 299

[5] COMPARTMENTALIZATION OF THE ACUTE CYTOKINE RESPONSE IN HUMANS AFTER INTRAVENOUS ENDOTOXIN ADMINISTRATION [J]. JOURNAL OF APPLIED PHYSIOLOGY, 1993, 74 (06) : 3027 - 3033

[6] HIGH CIRCULATING LEVELS OF INTERLEUKIN-6 IN PATIENTS WITH SEPTIC SHOCK - EVOLUTION DURING SEPSIS, PROGNOSTIC VALUE, AND INTERPLAY WITH OTHER CYTOKINES [J]. AMERICAN JOURNAL OF MEDICINE, 1991, 91 (01) : 23 - 29

[7] PLASMA CYTOKINE AND ENDOTOXIN LEVELS CORRELATE WITH SURVIVAL IN PATIENTS WITH THE SEPSIS SYNDROME [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (08) : 771 - 778

[8] STRATEGIES FOR BLOCKING THE SYSTEMIC EFFECTS OF CYTOKINES IN THE SEPSIS SYNDROME [J]. CRITICAL CARE MEDICINE, 1995, 23 (05) : 955 - 963

[9] TUMOR-NECROSIS-FACTOR AS THE PROXIMAL MEDIATOR OF SEPSIS - OR THIS TOO WILL PASS [J]. CRITICAL CARE MEDICINE, 1995, 23 (09) : 1457 - 1458

[10] DELLINGER RP, 1992, UPDATE INTENSIVE CAR, V16, P289